Figure 1. TIGIT as a co-inhibitory receptor that critically limits anti-tumor and other CD8+ T cell-dependent chronic immune responses. TIGIT competes with CD226 for binding the receptor PVR, and disrupts CD226 dimerization in cis at the cell surface. TIGIT collaborates with PD1 to limit chronic CD8+ T cell responses, and anti-antibody co-blockade of TIGIT and PD-L1 enhance CD8+ T cell effector function, resulting in enhanced tumor and chronic viral clearance.
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
To request a reprint or corporate permissions for this article, please click on the relevant link below:
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
Obtain permissions instantly via Rightslink by clicking on the button below:
If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.
